Pharmacology & ToxicologyAmerican Journal of Physiology-Heart and Circulatory PhysiologyPeer-reviewed
The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Nav1.5 channels
Jakob Sauer, Jessica Marksteiner, Martin HOHENEGGER…·Oliver Kudlacek
This study shows empagliflozin enhances peak sodium current in Nav1.5 channels by acting as a pharmacological chaperone, potentially reducing arrhythmia risk in Duchenne muscular dystrophy.